Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 13/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868180 | 0.85 | MKNK1 (0.47) | MKNK1F2RL3RAB9AMEN1MAPK1 | |
| SCHEMBL3867956 | 0.84 | F2RL3 (0.44) | MKNK1F2RL3SMN1; SMN2 | |
| SCHEMBL3871955 | 0.81 | MKNK1 (0.71) | MKNK1 | |
| SCHEMBL3869278 | 0.78 | CHRNB1 (0.49) | MKNK1F2RL3 | |
| SCHEMBL15473971 | 0.78 | ADORA2A (0.41) | LMNAHPGDKMT2A | |
| SCHEMBL3871956 | 0.76 | MKNK1 (0.40) | MKNK1RAB9AMEN1MAPK1KMT2A | |
| SCHEMBL4049609 | 0.76 | L3MBTL1 (0.39) | LMNA | |
| SCHEMBL3868156 | 0.75 | HRH3 (0.48) | MKNK1F2RL3NPC1LMNAHPGD | |
| SCHEMBL3865641 | 0.74 | DNMT1 (0.46) | MKNK1F2RL3DNMT1EHMT2 | |
| SCHEMBL3869345 | 0.69 | F2RL3 (0.49) | MKNK1F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | claimed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | MKNK1 299/4885F2RL3 3095/4885NPC1 3954/4885 |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CDK2, CDK1, MAP4K2 | MKNK1 299/4885F2RL3 3095/4885NPC1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.